Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer

Cancer - United States
doi 10.1002/cncr.26555
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology
Oncology
2018English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

Cardio-Oncology
2019English

Safety Assessment of Neoadjuvant Pertuzumab Combined With Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy